# Christian Jackisch

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/christian-jackisch/

## Facts

| Field | Value |
| --- | --- |
| Citations | 41,939 |
| Field | Breast Cancer Treatment Studies |
| h-index | 90 |
| i10-index | 262 |
| Last Known Institution | Goethe University Frankfurt |
| OpenAlex ID | https://openalex.org/A5016987068 |
| ORCID iD | https://orcid.org/0000-0001-8537-3743 |
| Works | 836 |

## Researcher papers

- [Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-breast-cancer/)
- [Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes](https://scholariq.org/papers/definition-and-impact-of-pathologic-complete-response-on-prognosis-after/)
- [Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-emtansine-for-residual-invasive-her2-positive-breast-cancer/)
- [Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy](https://scholariq.org/papers/tumour-infiltrating-lymphocytes-and-prognosis-in-different-subtypes-of-breast/)
- [Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial](https://scholariq.org/papers/neoadjuvant-carboplatin-in-patients-with-triple-negative-and-her2-positive-early/)
- [Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers](https://scholariq.org/papers/tumor-infiltrating-lymphocytes-and-response-to-neoadjuvant-chemotherapy-with-or/)
- [A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study](https://scholariq.org/papers/a-randomised-phase-ii-study-investigating-durvalumab-in-addition-to-an/)
- [Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials](https://scholariq.org/papers/clinical-and-molecular-characteristics-of-her2-low-positive-breast-cancer-pooled/)
- [Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study](https://scholariq.org/papers/neoadjuvant-treatment-with-trastuzumab-in-her2-positive-breast-cancer-results/)
- [Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial](https://scholariq.org/papers/bevacizumab-and-platinum-based-combinations-for-recurrent-ovarian-cancer-a/)
- [13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus - Opinion of a German Team of Experts (Zurich 2013)](https://scholariq.org/papers/13th-st-gallen-international-breast-cancer-conference-2013-primary-therapy-of/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

## Researcher university

- [Goethe University Frankfurt](https://scholariq.org/institutions/goethe-university-frankfurt/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.